Total Payments
$3,373
2024 Payments
$773.51
Companies
16
Transactions
209
Medicare Patients
17,560
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$2,947 (87.4%)
Education$425.78 (12.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,947 | 201 | 87.4% |
| Education | $425.78 | 8 | 12.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $806.70 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $534.54 | 32 | $0 (2022) |
| UCB, Inc. | $360.36 | 24 | $0 (2024) |
| LEO Pharma Inc. | $311.58 | 23 | $0 (2023) |
| Lilly USA, LLC | $280.22 | 16 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $264.64 | 30 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $149.58 | 12 | $0 (2024) |
| AbbVie Inc. | $130.13 | 7 | $0 (2021) |
| PFIZER INC. | $119.39 | 7 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $109.90 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $773.51 | 56 | UCB, Inc. ($324.60) |
| 2023 | $152.71 | 15 | E.R. Squibb & Sons, L.L.C. ($130.21) |
| 2022 | $91.12 | 3 | Janssen Biotech, Inc. ($78.16) |
| 2021 | $110.09 | 3 | Janssen Biotech, Inc. ($93.14) |
| 2020 | $104.86 | 5 | UCB, Inc. ($35.76) |
| 2019 | $463.36 | 21 | Lilly USA, LLC ($140.66) |
| 2018 | $667.16 | 41 | Novartis Pharmaceuticals Corporation ($235.50) |
| 2017 | $1,010 | 65 | Janssen Biotech, Inc. ($213.72) |
All Payment Transactions
209 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.07 | General |
| Category: Immunology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.53 | General |
| Category: Immunology | ||||||
| 12/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: DERMATOLOGY | ||||||
| 11/25/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Dermatology | ||||||
| 11/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Immunology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.08 | General |
| Category: Immunology | ||||||
| 11/18/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: DERMATOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Dermatology | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $11.07 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: Dermatology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $11.93 | General |
| Category: Immunology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $6.20 | General |
| Category: Immunology | ||||||
| 10/02/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Dermatology | ||||||
| 09/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $9.57 | General |
| Category: Immunology | ||||||
| 09/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $6.35 | General |
| Category: Immunology | ||||||
| 09/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $9.90 | General |
| Category: Immunology | ||||||
| 08/29/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: Dermatology | ||||||
| 08/26/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: Immunology | ||||||
| 08/14/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $10.43 | General |
| Category: Immunology | ||||||
| 08/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 4,346 | 6,474 | $1.3M | $336,372 |
| 2022 | 34 | 4,622 | 7,124 | $1.4M | $362,528 |
| 2021 | 39 | 4,808 | 7,689 | $1.5M | $401,030 |
| 2020 | 33 | 3,784 | 6,452 | $1.2M | $289,869 |
Total Patients
17,560
Total Services
27,739
Medicare Billing
$1.4M
Procedure Codes
139
All Medicare Procedures & Services
139 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,107 | 1,455 | $312,825 | $88,989 | 28.4% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 473 | 756 | $226,800 | $41,583 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 247 | 339 | $101,700 | $31,277 | 30.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 592 | 731 | $149,855 | $28,694 | 19.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 341 | 385 | $103,024 | $27,777 | 27.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 251 | 280 | $99,400 | $22,736 | 22.9% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 37 | 44 | $17,820 | $13,249 | 74.3% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 33 | 107 | $32,635 | $10,555 | 32.3% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 85 | 98 | $40,942 | $9,980 | 24.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 197 | 223 | $30,105 | $8,793 | 29.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 370 | 1,232 | $36,960 | $6,454 | 17.5% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 37 | 41 | $20,775 | $5,596 | 26.9% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 37 | 43 | $15,330 | $4,617 | 30.1% |
| 17271 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 30 | 34 | $16,002 | $4,091 | 25.6% |
| 17281 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 28 | 30 | $15,350 | $4,073 | 26.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 54 | 54 | $14,310 | $3,642 | 25.5% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $10,570 | $2,896 | 27.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 55 | 63 | $8,890 | $2,557 | 28.8% |
| 69100 | Biopsy of ear | Office | 2023 | 33 | 36 | $10,497 | $2,118 | 20.2% |
| 17260 | Destruction of cancer skin growth of trunk, arms, or legs, 0.5 cm or less | Office | 2023 | 34 | 36 | $9,998 | $2,070 | 20.7% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 13 | 14 | $7,512 | $2,008 | 26.7% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 20 | 23 | $5,570 | $1,793 | 32.2% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 19 | 20 | $7,305 | $1,716 | 23.5% |
| 17280 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 15 | 16 | $6,482 | $1,642 | 25.3% |
| 17270 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 0.5 cm or less | Office | 2023 | 11 | 13 | $5,655 | $1,368 | 24.2% |
About Dr. Mark Blumberg, M.D
Dr. Mark Blumberg, M.D is a Dermatopathology healthcare provider based in Springfield, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1588662019.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Blumberg, M.D has received a total of $3,373 in payments from pharmaceutical and medical device companies, with $773.51 received in 2024. These payments were reported across 209 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,947).
As a Medicare-enrolled provider, Blumberg has provided services to 17,560 Medicare beneficiaries, totaling 27,739 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 139 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatopathology
- Other Specialties Dermatology
- Location Springfield, MA
- Active Since 07/08/2005
- Last Updated 12/18/2025
- Taxonomy Code 207ND0900X
- Entity Type Individual
- NPI Number 1588662019
Products in Payments
- COSENTYX (Biological) $534.54
- Bimzelx (Biological) $324.60
- TREMFYA (Drug) $319.84
- Tremfya (Drug) $298.90
- ENSTILAR (Drug) $284.58
- TALTZ (Drug) $280.22
- Sotyktu (Drug) $264.64
- Zoryve (Drug) $149.58
- STELARA (Biological) $147.08
- DUPIXENT (Drug) $106.91
- EUCRISA (Drug) $104.12
- Enbrel (Biological) $96.47
- DUPIXENT DUPILUMAB INJECTION (Biological) $94.96
- Humira (Biological) $73.29
- REMICADE (Biological) $40.88
- ILUMYA (tildrakizumab-asmn) injection (Biological) $40.87
- Cimzia (Drug) $35.76
- SKYRIZI (Biological) $33.24
- EPIDUO FORTE (Drug) $27.34
- ADBRY (Biological) $22.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.